Voglibose

Key Product Details

Product Description

Voglibose is an orally active α-glucosidase inhibitor (IC₅₀ values are 3.9 and 6.4 nM at sucrase and maltase respectively). Increases glucagon-like peptide 1 (GLP-1) secretion and decreases food consumption in ob/ob mice, and reduces plasma concentrations of glucose, triglycerides and insulin in Wistar fatty rats. Exhibits antidiabetic and antiobesity activity in vivo.

Product Specifications for Voglibose

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Voglibose

The following data is based on the product molecular weight 267.28.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.74 mL	18.71 mL	37.41 mL
5 mM	0.75 mL	3.74 mL	7.48 mL
10 mM	0.37 mL	1.87 mL	3.74 mL
50 mM	0.07 mL	0.37 mL	0.75 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Matsui α-Glucosidase inhibition assay in an enzyme-immobilized amino-microplate. Anal.Sci. 2009 PMID: 19359799
• Moritoh Chronic administration of voglibose, an α-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J.Pharmacol.Exp.Ther. 2009 PMID: 19208898
• Matsuo Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Am.J.Clin.Nutr. 1992 PMID: 1728846

Product Documents for Voglibose